On March 2, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum platform, reported its participation in a series of major international industry events taking place in March 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics.
BIO-Europe Spring: Primary Focus on Strategic Partnerships
Defence will participate in BIO-Europe Spring (March 23–26, Lisbon, Portugal), the premier global partnering event for the life sciences industry. At BIO-Europe, the Company will prioritize discussions with biopharmaceutical partners seeking to collaborate on enhancing the intracellular delivery and efficacy of their ADC programs using Accum.
DCAT Week: Advancing Biomanufacturing Capabilities
Defence will also attend DCAT Week (March 23–26, New York), where the Company will focus on strengthening its manufacturing strategy. During DCAT, Defence plans to meet with contract research and manufacturing partners to advance the robust and high-quality biomanufacturing of Accum, a key operational objective for the Company. Defence has recently become a member of the Drug, Chemical & Associated Technologies Association ("DCAT"), reinforcing its commitment to ensuring the well-characterized, quality-controlled, and commercially ready production of Accum.
Expanding U.S. Presence and Investor Engagement
In parallel, Defence will participate in the South Florida Life Sciences Showcase (March 24, Miami) and FII PRIORITY Miami (March 25–27), supporting the Company’s ongoing investor outreach and business development efforts in the United States. Defence has also recently joined BioFlorida, further strengthening its footprint within the Florida life sciences ecosystem.
"As we engage with partners and industry stakeholders across these key events, our priority is to build meaningful collaborations that support the continued growth and adoption of Accum," said Sébastien Plouffe, CEO of Defence Therapeutics. "By enabling more efficient intracellular delivery of complex biologics, Accum has the potential to significantly enhance therapeutic performance and tolerability, positioning the platform as a game-changing solution in the ADC field.". To explore partnering opportunities or schedule a meeting, please contact Defence Therapeutics at [email protected].
(Press release, Defence Therapeutics, MAR 2, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-to-showcase-accum-platform-at-key-international-industry-events-in-march [SID1234663176])